Skip to content

Study · Animal study (in vivo) · rat · 2003

10 results

Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles.

Suwa M, Nakano H, Kumagai S

Journal of applied physiology (Bethesda, Md. : 1985)30 May 2003Cited by 203 (Europe PMC)

PMID12777406 (opens in a new tab)DOI10.1152/japplphysiol.00349.2003 (opens in a new tab)PepBankPUB-12777406
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rat EDL muscle, AICAR decreased the percentage of type IIB fibers.

    In plain wordsIn rats, AICAR reduced the proportion of type IIB muscle fibers.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseType IIB fibers
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    AICAR treatment caused a significant decrease in the percentage of type IIB fibers and the concomitant increase in the percentage of type IIX fibers in extensor digitorum longus (EDL) muscle.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rat EDL muscle, AICAR increased the percentage of type IIX fibers.

    In plain wordsIn rats, AICAR increased the proportion of type IIX muscle fibers.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseType IIX fibers
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    AICAR treatment caused a significant decrease in the percentage of type IIB fibers and the concomitant increase in the percentage of type IIX fibers in extensor digitorum longus (EDL) muscle.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR did not alter capillary density.

    In plain wordsIn rats, AICAR did not change muscle capillary density.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeCapillary density
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    The capillary density and the capillary-to-fiber ratio were not altered by AICAR.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR did not alter the capillary-to-fiber ratio.

    In plain wordsIn rats, AICAR did not change the ratio of capillaries to muscle fibers.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeCapillary-to-fiber ratio
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    The capillary density and the capillary-to-fiber ratio were not altered by AICAR.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR increased glycolytic enzyme activities.

    In plain wordsIn rats, AICAR increased glycolytic enzyme activities in muscle.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseGlycolytic enzyme activities
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    AICAR treatment increased the glycolytic and oxidative enzyme activities but not the antioxidant enzyme activities.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR increased oxidative enzyme activities.

    In plain wordsIn rats, AICAR increased oxidative enzyme activities in muscle.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseOxidative enzyme activities
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    AICAR treatment increased the glycolytic and oxidative enzyme activities but not the antioxidant enzyme activities.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR did not increase antioxidant enzyme activities.

    In plain wordsIn rats, AICAR did not increase antioxidant enzyme activities in muscle.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeAntioxidant enzyme activities
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    AICAR treatment increased the glycolytic and oxidative enzyme activities but not the antioxidant enzyme activities.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rat EDL muscle, AICAR increased UCP3 levels.

    In plain wordsIn rats, AICAR increased UCP3 protein in EDL muscle.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseUCP3 level
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    The AICAR treatment increased the uncoupling protein 3 (UCP3) level in EDL and the peroxisome proliferator-activated receptor-gamma coactivator-1alpha protein level in the soleus and EDL muscles, whereas the myogenin level was not altered by AICAR.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In rat soleus and EDL muscles, AICAR increased PGC-1alpha protein levels.

    In plain wordsIn rats, AICAR increased PGC-1alpha protein in soleus and EDL muscles.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreasePGC-1alpha protein
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    The AICAR treatment increased the uncoupling protein 3 (UCP3) level in EDL and the peroxisome proliferator-activated receptor-gamma coactivator-1alpha protein level in the soleus and EDL muscles, whereas the myogenin level was not altered by AICAR.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In rat muscles, AICAR did not alter myogenin levels.

    In plain wordsIn rats, AICAR did not change muscle myogenin levels.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeMyogenin level
    Study

    ratn: not reported in source

    skeletal muscles
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 14 successive daysAs given in this study (rat).

    Source sentences

    Summary
    The AICAR treatment increased the uncoupling protein 3 (UCP3) level in EDL and the peroxisome proliferator-activated receptor-gamma coactivator-1alpha protein level in the soleus and EDL muscles, whereas the myogenin level was not altered by AICAR.
    1 context sentence
    Summary · context
    This study was designed to determine the histological and metabolic effects of the administration of 5'-AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 14 successive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.